[en] Despite its intensive use in adjuvant breast cancer therapy for more than 30 years, the exact mechanisms of action of tamoxifen have not yet been fully characterized. Tamoxifen was recently shown to restore the E-cadherin function of human breast cancer MCF7/6 cells and to suppress their invasive phenotype. Because tamoxifen interacts with targets implicated in Ca2+ homeostasis, we explored the possibility that the restoration of E-cadherin function in MCF7/6 cells induced by this drug could be affected by Ca2+ modulators. Two different Ca2+ channel antagonists (verapamil and nifedipine) potentiated the effect of tamoxifen on E-cadherin function, as evaluated with a fast cell aggregation assay. These molecules decreased the tamoxifen concentration needed to restore the E-cadherin function from 10(-6) M to 10(-7) M. When incubated with a Ca2+ channel agonist, Bay K8644 (methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoro-methylphenyl)- pyridine-5-carboxylate), the effect of tamoxifen on E-cadherin function was completely abolished. These results demonstrate that the restoration of the E-cadherin function induced by tamoxifen depends, at least in part, on a Ca2+ pathway, and support the evidence of an effect of tamoxifen on Ca(2+)-dependent mechanisms. Our data also suggest that Ca2+ channel modulators could make it possible to decrease the dose of tamoxifen administered to patients without reducing the therapeutic effects.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Charlier, Corinne ; Université de Liège - ULiège > Département de pharmacie > Chimie toxicologique
Bruyneel, E.
Lechanteur, Chantal ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Bracke, M.
Mareel, M.
Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire
Language :
English
Title :
Enhancement of Tamoxifen-Induced E-Cadherin Function by Ca2+ Channel Antagonists in Human Breast Cancer Mcf7/6 Cells
Antoniotti, S., P. Maggiora, C. Dati and M. De Bortoli, 1992, Tamoxifen up-regulates cerb-B2 expression in oestrogen-responsive breast cancer cells in vitro, Eur. J. Cancer 28, 318.
Baker, V.A., J.R. Puddefoot, S. Marsigliante, S. Baker, A.W. Goode and G.P. Vinson, 1992, Oestrogen receptors isoforms, their distribution and relation to progesterone receptor level in breast cancer samples, Br. J. Cancer 66, 1083.
Bracke, M.E., C. Charlier, E.A. Bruyneel, C. Labit, M.M. Mareel and V. Castronovo, 1994, Tamoxifen restores the E-cadherin function in human breast cancer MCF7/6 cells and suppresses their invasive phenotype, Cancer Res. 54, 4607.
Castoria, G., A. Migliaccio, E. Nola and F. Auricchio, 1988, In vitro interaction of oestradiol receptor with Ca-calmodulin, Mol. Endocrinol. 2, 167.
Charlier, C., C. Colin, M.P. Merville, J. Gielen, R. Lambotte, G. Plomteux and V. Castronovo, 1994, Le tamoxifène dans le traitement du cancer du sein, J. Gynécol. Obstét. Biol. Reprod. 23, 751.
Charlier, C., A. Chariot, N. Antoine, M.P. Merville, J. Gielen and V. Castronovo, 1995, Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB435 cells, Biochem. Pharmacol. 49, 351.
Coezy, E., J.L. Borgna and H. Rochefort, 1982, Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth, Cancer Res. 42, 317.
Fisher, B., J. Costantino, C. Redmond, R. Poisson, D. Bowman, J. Couture, V.D. Nikolay, N. Wolmark, D.L. Wickerman, E.R. Fisher, R. Margolese, A. Robidoux, H. Shibata, J. Terz, A.H.G. Paterson, M.I. Feldman, W. Farrar, J. Evans, H.L. Lickley and M. Ketner, 1989, A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors, New Engl. J. Med. 320, 479.
Fuqua, S.A.W., G.C. Chamness and W.L. McGuire, 1993, Estrogen receptor mutations in breast cancer, J. Cell. Biochem. 51, 135.
Gupta, V., N. Kamath, G.T. Tkalcevic and S.V. Singh, 1994, Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line, Biochem. Pharmacol. 47, 1701.
Jeng, M.H., P. Ten Dijke, K.K. Iwata and V.C. Jordan, 1993, Regulation of the levels of three transforming growth factor β mRNAs by estrogen and their effects on the proliferation of human breast cancer cells, Mol. Cell. Endocrinol. 97, 115.
Osborne, C.K., D.H. Boldt, G.M. Clark and J.M. Trent, 1983, Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase, Cancer Res. 43, 3583.
Shapiro, L., A.M. Fannon, P.D. Kwong, M.S. Lehmann, G. Grübel, J.-F. Legrand, J. Als-Nielsen, D.R. Colman and W.A. Hendrickson, 1995, Structural basis of cell-cell adhesion by cadherins, Nature 374, 327.
Soule, H.D., J. Vazquez, A. Long, S. Albert and M. Brennan, 1973, A human cell line of a pleural effusion derived from a breast carcinoma, J. Natl. Cancer Inst. 51, 1409.
Strobl, J.S., V.A. Peterson and K.A. Woodfork, 1994, A survey of human breast cancer sensitivity to growth inhibition by calmodulin antagonists in tissue culture, Mol. Endocrinol. 2, 167.
Wiseman, H., M. Cannon, H.R. Arnstein and B. Halliwell, 1993, Tamoxifen inhibits lipid peroxidation in cardiac microsomes, Biochem. Pharmacol. 45, 1851.
